Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo. Etiam sapien elit, consequat eget, tristique non, venenatis quis, ante. Mauris tincidunt sem sed arcu. Nunc auctor. Mauris dictum facilisis augue. Phasellus faucibus molestie nisl. Nullam dapibus fermentum ipsum. Aliquam erat volutpat. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab
Women’s dress
Related products
-
Select options This product has multiple variants. The options may be chosen on the product pageSpecification Product Details Brand Name Wegovy Active Ingredient Semaglutide (GLP-1 Receptor Agonist) Administration Route Subcutaneous Injection (Once Weekly) Available Dosages 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg Primary Indication Chronic Weight Management / Obesity Treatment Storage Requirements Refrigerate at 2°C to 8°C (Do not freeze) Manufacturer Novo Nordisk -
Add to cartFeature Specification Product Name Mysimba Active Ingredients Naltrexone hydrochloride (8 mg) / Bupropion hydrochloride (90 mg) Dosage Form Prolonged-release tablets Primary Indication Chronic weight management in adults Mechanism Targets central nervous system pathways regulating food intake and energy expenditure Manufacturer Central Medical Supplies / Approved European Distributors -
Add to cartFeature Specification Details Active Ingredient Tirzepatide (Dual GIP / GLP-1 Receptor Agonist) Bundle Contents 1 x 2.5mg KwikPen (4 doses) + 1 x 5mg KwikPen (4 doses) Total Duration 8 Weeks of continuous medical treatment Administration Route Subcutaneous injection (Once weekly) Storage Protocols Refrigerate at 2°C – 8°C; Unrefrigerated stable up to 30 days below 30°C Target Indications Chronic weight management, metabolic support, and obesity care -
Add to cartAttribute Specification Product Name Mounjaro Bundles (Maintenance & Escalation Phase) Available Strengths 5mg / 0.5mL and 7.5mg / 0.5mL Active Ingredient Tirzepatide (Dual GIP and GLP-1 Receptor Agonist) Administration Route Subcutaneous Injection (Once-Weekly) Primary Indication Chronic Weight Management & Type 2 Diabetes Adjunct Packaging Configuration Multi-dose pre-filled injection pens (4-week supply per strength) Storage Requirements Refrigerated storage ($2^\circ\text{C}$ to $8^\circ\text{C}$), do not freeze -
Select options This product has multiple variants. The options may be chosen on the product pageThis is a variable product.
Etiam bibendum elit eget erat. Curabitur bibendum justo non orci. Cras elementum. In dapibus augue non sapien. Morbi imperdiet, mauris ac auctor dictum, nisl ligula egestas nulla, et sollicitudin sem purus in lacus. Praesent dapibus.